Deep Lens raises $14M for AI-powered clinical trial recruitment

Jackie Drees - Print  | 

Deep Lens, an artificial intelligence digital pathology company, received $14 million in funding to expand its AI platform for recruiting clinical trial participants.

The platform, called Viper, combines deep learning technology with pathology workflows to facilitate patient identification for clinical trials. The software, which aims to facilitate peer-to-peer collaboration and clinical research pathologists, can flag trial-eligible patients at the time of diagnosis.

"With this additional capital, we will move to quickly leverage our successes in the pathology industry and apply a highly disruptive approach to patient identification in clinical trials, one of the most expensive and time intensive issues faced by the pharmaceutical industry," Deep Lens President and co-founder Simon Arkell said in a news release.

More articles on artificial intelligence:
Vox Media: AI can easily be fooled
American College of Radiology, Nvidia team up to deploy AI in radiology
Berkeley Lab researchers use AI to determine veterans' suicide risk

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.